OBG Pharmaceuticals

What OBG Pharmaceuticals does

OBG Pharmaceuticals (legally OBG Company Ltd, doing business as The O'Brien Group) is a privately held United Kingdom holding company headquartered at Ayrton House, Parliament Business Park, Commerce Way, Liverpool (L8 7BA). The group is organized into two horizontal business units: a Pharmaceutical Division housing the Ayrtons and Ransom Naturals sub-brands, and a Plastics and Industrial Additives Division housing the RBH and Hubron sub-brands. Each sub-brand is recorded as an acquired brand retained under the group umbrella, indicating a roll-up/hold-and-operate model rather than a centralized product platform. Geographic reach is limited to the UK within documented operating geographies, with a broader Europe market reference. The company is actively operating and recruiting, and is privately held with no public listing, no disclosed funding rounds, no M&A transactions on record beyond the historical retention of its four sub-brands, and no disclosed leadership team, revenue, or headcount.

The stated value proposition is enabling entrepreneurial spirit in science-led markets with a sustainable-enterprise focus, positioning the group against larger corporate competitors. Customer segments are described at the business-unit level rather than as named logos: pharmaceutical industry buyers seeking sustainable enterprise partners and plastics manufacturers procuring industrial additives. Pricing models, distribution channels, customer counts, average contract values, and revenue mechanics are not publicly disclosed; the website functions as a corporate-informational presence rather than a product-commerce channel, and the four sub-brands operate independent external websites (ayrtons.com, ransomnaturals.com, rbhltd.com, hubron.com) for their own market-facing activity. The group's primary contact channel is a single UK telephone number (+44 (0)151 709 2074) and a contact form at the Liverpool head office.

There is no disclosed technology stack, no API/SDK/integration footprint, no proprietary software product, no AI/ML capability, and no patents or trademarks on file. The only documented compliance posture is adherence to the UK Data Protection Act 1998 in handling recruitment-related personal data. Go-to-market motion is not described; marketing is limited to the corporate website and a CoreHR-hosted external job portal. The overall evidence base is thin for an investment-grade assessment: revenue, headcount, leadership, funding, and transaction history are all undisclosed or unknown, and analytical conclusions must therefore rest on structural facts only.

Name

OBG Pharmaceuticals

Legal name

OBG Company Ltd

Website

https://obg.co.uk

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

OBG Pharmaceuticals (legally OBG Company Ltd, doing business as The O'Brien Group) is a privately held UK holding company operating a Pharmaceutical Division (Ayrtons, Ransom Naturals) and a Plastics and Industrial Additives Division (RBH, Hubron), supporting specialty B2B enterprises.

Ownership category

akta.pro rank

Headquarters

HQ city

Liverpool

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Marketing channels1 record

Core offering

OBG Pharmaceuticals operates as a UK-based holding company (The O'Brien Group) managing two divisions: a Pharmaceutical Division offering products under the Ayrtons and Ransom Naturals brands, and a Plastics and Industrial Additives Division supplying materials under the RBH and Hubron brands. The group focuses on enabling entrepreneurial activity in science-led markets with an emphasis on sustainable enterprise.

Product overview

OBG (The O'Brien Group) operates as a holding company managing two main divisions: a Pharmaceutical Division comprising Ayrtons and Ransom Naturals brands, and a Plastics and Industrial Additives Division comprising Rbh and Hubron brands. The company focuses on enabling entrepreneurial spirit in science-led markets with an emphasis on sustainable enterprise.

Differentiator

Problem solved

Functional benefit

Products and services

• Ayrtons A pharmaceutical brand operating under OBG's Pharmaceutical Division, providing pharmaceutical products and solutions to science-led markets.
• Ransom Naturals A natural health products brand operating under OBG's Pharmaceutical Division, specializing in natural health offerings.
• RBH A brand within OBG's Plastics and Industrial Additives Division, serving the industrial additives market.
• Hubron A brand within OBG's Plastics and Industrial Additives Division, specializing in industrial plastics and additives.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• AyrtonscoreOthersAyrtons is listed under the Pharmaceutical Division of The O'Brien Group (OBG). It operates as part of the group structure focused on pharmaceutical products and solutions.
• Ransom NaturalscoreOthersRansom Naturals is listed under the Pharmaceutical Division of The O'Brien Group (OBG). It operates as part of the group structure, specializing in natural health products.
• RBH (Rbh)coreOthersRBH is listed under the Plastics and Industrial Additives Division of The O'Brien Group (OBG). It operates as part of the group structure serving the industrial additives market.
• HubroncoreOthersHubron is listed under the Plastics and Industrial Additives Division of The O'Brien Group (OBG). It operates as part of the group structure specializing in industrial plastics and additives.

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Croda International: UK-listed specialty chemicals company with a portfolio of acquired and organically built additives and life sciences brands. Most directly comparable to OBG's industrial additives division (Hubron, RBH) on product category and target end-markets such as polymers and personal care.
• Hikma Pharmaceuticals: UK-headquartered pharmaceutical group with a broad generics and specialty pharma portfolio across multiple geographies. Comparable to OBG's pharmaceutical division (Ayrtons, Ransom Naturals) as a UK-rooted pharma business with diversified branded and generic offerings.
• Halma plc: UK-listed group that holds a portfolio of niche, science-led operating companies with strong autonomy. Highly comparable to OBG's holding-company-as-pure-play model of running acquired sub-brands (Ayrtons, Ransom Naturals, RBH, Hubron) under one group entity.
• Johnson Matthey: UK-listed specialty chemicals and materials company with multiple operating divisions serving industrial and life sciences markets. Comparable to OBG in operating a multi-division UK-headquartered science-led portfolio with industrial chemistry and pharma/health adjacencies.
• Synthomer plc: UK-listed specialty polymers and additives producer serving industrial customers. Directly comparable to Hubron and RBH as a UK-rooted specialty additive platform focused on polymer and industrial applications.
• Element Solutions Inc: Global specialty chemicals platform built via acquisitions of niche formulation and additives businesses. Comparable to OBG's roll-up structure of acquired specialty brands operating semi-independently under one platform.
• Stepan Company: US-listed specialty chemicals manufacturer with diversified end-market exposure including polymers and personal care. Comparable to OBG's industrial additives division on product category and to the broader group on multi-market, multi-division specialty chemistry positioning.
• Wacker Chemie: German specialty chemicals group with diversified portfolios in silicones, polymers, and biosolutions. Comparable to OBG as a multi-divisional specialty chemicals platform with both industrial and life sciences-adjacent product lines.

Direct peers

• Cabot Corporation: Global specialty chemicals and performance materials company with a leading carbon black franchise. Directly comparable to Hubron's specialty carbon black and additives business on product category and industrial customer base.

Others

• 3i Group plc: UK-listed investment company that builds value by acquiring and operating science-led and industrial businesses. Comparable to OBG at the holding-company level as an owner-operator of UK-based specialty assets, though operating through public markets rather than as a private family office.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OBG Pharmaceuticals